The historical rank and industry rank for F-star Therapeutics's Net Cash per Share or its related term are showing as below:
FSTX'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.8 Med: 3.22 Max: 17.8
Current: 17.8
During the past 3 years, the highest Price-to-Net-Cash Ratio of F-star Therapeutics was 17.80. The lowest was 1.80. And the median was 3.22.
FSTX's Price-to-Net-Cash is not ranked
in the Biotechnology industry.
Industry Median: 4.14
vs FSTX: 17.80
F-star Therapeutics Net Cash per Share Historical Data
The historical data trend for F-star Therapeutics's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of F-star Therapeutics's Net Cash per Share
For the Biotechnology subindustry, F-star Therapeutics's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
F-star Therapeutics's Price-to-Net-Cash Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, F-star Therapeutics's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where F-star Therapeutics's Price-to-Net-Cash falls into.
F-star Therapeutics Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
F-star Therapeutics's Net Cash per Share for the fiscal year that ended in Dec. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
F-star Therapeutics (NAS:FSTX) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
F-star Therapeutics Net Cash per Share Related Terms
Thank you for viewing the detailed overview of F-star Therapeutics's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
F-star Therapeutics (F-star Therapeutics) Business Description
F-star Therapeutics Inc is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the company's goal is to offer patients greater and more durable benefits than immuno-oncology treatments.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FSTX has been successfully added to your 